Burnaby, BC Biotechnology and Pharmaceutical Companies directory and business contacts list
The following Burnaby, BC, Canada Biotechnology and Pharmaceutical Companies are among the many key British Columbia organizations listed in the BC Contacts Directory.Try BC Contacts today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Cathy Shevchuk, Operations Manager
JR Laboratories Inc.
12 - 3871 North Fraser Way
Burnaby, BC V5J 5G6
Tel. 604 432-9311
Fax. 604 432-7768
cshevchuk0f76bf@jrlabs.ca
info0f76bf@jrlabs.ca
www.jrlabs.ca
Dr. Humbert DelliColli, Director of Lignin Development
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
HDelliColli403nc6bt@lignol.ca
info403nc6bt@lignol.ca
www.lignol.ca
Dr. DelliColli has more than 30 years of experience in the development and production of lignin and other specialty chemicals. Prior to joining Lignol, Dr. DelliColli held a series of progressively senior positions with MeadWestvaco Corporation, the world's leading commercial-scale producer of Kraft lignin derivatives.
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageHeather Harris-Harper, Director, Clinical Operations, CANTEST Clinical Research
CANTEST Ltd. - Burnaby (div. of Maxxam Analytics International Corporation)
4606 Canada Way
Burnaby, BC V5G 1K5
Tel. 604 734-7276
Fax. 604 731-2386
cantestm1nutkd@cantest.com
www.cantest.com
January 30, 2007 - As Director, Clinical Operations, Ms. Harris-Harper's responsibilities include the direction, planning and execution of clinical trials, ensuring operational excellence for CANTEST Clinical Research's international corporate clientele.
Ms. Harris-Harper brings to CANTEST 20 years of experience in the conduct of pharmaceutical industry sponsored clinical trials and has held progressive positions in clinical trial monitoring, management and operational supervision at several leading multinational biotechnology and pharmaceutical companies.
Vijay Sondhi, Chief Financial Officer & Chief Operating Officer
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby, BC V5G 4W8
Tel. 604 484-3300
Fax. 604 484-3445
vsondhicp9x@xenon-pharma.com
infocp9x@xenon-pharma.com
www.xenon-pharma.com
Vijay Sondhi, Chief Financial Officer & Chief Operating Officer, joined Xenon in December 2004. Before joining Xenon, Mr. Sondhi spent 16 years in the high technology sector in Europe and the United States.
He held CFO and co-CEO positions with IXOS Software AG (subsequently acquired by Open Text Corporation) where he led the company's successful IPO on the NASDAQ and Frankfurt stock exchanges.
He was also CFO of Fidelio Software GmbH where he assisted in the sale of the company to MICROS Systems, Inc. Immediately prior to joining Xenon, Mr. Sondhi was Managing Director at Allianz Venture Partners, a EURO 300 million venture capital fund based in Munich.
He also served as a Venture Partner at Warburg Pincus in Europe. In addition, he has held several positions with Booz-Allen & Hamilton & SAP AG. Mr. Sondhi received an MBA from Columbia University, New York and a B.Sc. in Computer Science from the University of British Columbia, Vancouver.
Ross MacLachlan, President, Director and Chief Executive Officer
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 222-9800 X 107 - direct
Tel. 604 222-9800
Fax. 604 222-9801
RMacLachlan6qu12hjr@lignol.ca
info6qu12hjr@lignol.ca
www.lignol.ca
MacLachlan has extensive experience in project financing, including a former role in corporate finance at Haywood Securities Inc. Mr. MacLachlan also has a successful track record in technology development and marketing, having worked successfully with Xerox Canada and Systems Auditing, a company which he founded.
MacLachlan has worked with companies in both the conventional and alternative energy sectors. He has been actively involved in raising capital for emerging technology companies and has acted as consultant or director for many of them.
Humphrey Tebit, Biopharmaceutics
CANTEST Ltd. - Burnaby (div. of Maxxam Analytics International Corporation)
4606 Canada Way
Burnaby, BC V5G 1K5
Tel. 604 734-7276
Fax. 604 731-2386
HTebitifwco3j9l@cantest.com
cantestifwco3j9l@cantest.com
www.cantest.com
Kent Toy, Director of Finance
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
KToy0n639@lignol.ca
info0n639@lignol.ca
www.lignol.ca
Kent Toy has extensive finance and administration experience with a range of private and public technology companies, providing full financial reporting and project accounting management.
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageMark Murray, Ph.D., President & Chief Executive Officer
Tekmira Pharmaceuticals Corporation
200 - 8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Tel. 604 419-3200
Fax. 604 419-3201
infocjxwrz@inexpharm.com
www.tekmirapharm.com
See also
Mark Murray, Ph.D., President & Chief Executive Officer
Protiva Biotherapeutics Inc.
100 - 3480 Gilmore Way
Burnaby, BC V5G 4W7
Tel. 604 630-5063 - direct
Tel. 604 630-5061
Fax. 604 630-5103
informationcjxwrz@protivabio.com
www.protivabio.com
Dr. Mark Murray has led Protiva since its inception in the summer of 2000. Dr. Murray has over 25 years of experience in both the R&D and business development facets of the biotechnology industry.
He has held senior management positions at ZymoGenetics and Xcyte Therapies prior to joining Protiva. Since entering the biotechnology industry he has successfully completed numerous and varied partnering deals, directed successful product development programs, been responsible for strategic planning programs, raised financing and executed extensive business development initiatives.
During his R&D career, Dr. Murray worked extensively on three programs that resulted in FDA approved drugs, including the first growth factor protein approved for human use, a program he led for several years.
Dr. Murray obtained his Ph.D. from the University of Oregon Health Sciences University and was a Damon Runyon-Walter Winchell post-doctoral research fellow for three years at the Massachusetts Institute of Technology.
Cathy Cardinall, Quality Assurance and Safety Manager
JR Laboratories Inc.
12 - 3871 North Fraser Way
Burnaby, BC V5J 5G6
Tel. 604 432-9311
Fax. 604 432-7768
ccardinallziohm4p@jrlabs.ca
infoziohm4p@jrlabs.ca
www.jrlabs.ca
Dr. Clay Flowers, Director of Operations
Northern Lipids Inc.
8855 Northbrook Court
Burnaby, BC V5J 5J1
Tel. 604 222-2548
Fax. 604 222-2563
infot08q9lmm@northernlipids.com
www.northernlipids.com
Vinay Chhatre, Manager Sales & Business Development
Northern Lipids Inc.
8855 Northbrook Court
Burnaby, BC V5J 5J1
Tel. 604 638-5631 - direct
Tel. 604 222-2548
Fax. 604 222-2563
infogwhtl@northernlipids.com
www.northernlipids.com
Tammy Mullarky, Vice President, Strategic Planning and Business Development
Tekmira Pharmaceuticals Corporation
200 - 8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Tel. 604 419-3200
Fax. 604 419-3201
infoc1@inexpharm.com
www.tekmirapharm.com
September 29, 2008 - Tammy Mullarky has joined Tekmira effective immediately and will have responsibility for strategic planning and business development including securing additional licensing and collaborative research and development agreements for Tekmira's technology.
Ms. Mullarky joined Tekmira from Targeted Growth, Inc. where as Senior Vice President she was responsible for business functions including business development, intellectual property and finance. Prior to Targeted Growth, Ms. Mullarky was a senior executive at Epigenomics, AG where she completed a $100 million diagnostics partnership.
Ms. Mullarky also has experience as a venture capital partner and was a founder and senior executive at AnorMed Inc. Before AnorMed, she was a member of the corporate mergers and acquisitions team for F. Hoffmann- La Roche. Ms. Mullarky has a M.A. in Science Management from the Massachusetts Institute of Technology and a B.A. in Chemistry from Whitman College.
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageOreola Donini, Ph.D., Senior Director, Preclinical R&D
Inimex Pharmaceuticals Inc.
8540 Baxter Place
Burnaby BC V5A 4T8
Tel. 604 225-2251
Fax. 604 225-2257
infoz8kg4f7gq@inimexpharma.com
www.inimexpharma.com
Dr. Donini has 10 years experience in drug discovery, optimization and development and has lead the discovery, selection and advancement of Inimex' lead drug candidate, IMX942.
Prior to joining Inimex, Dr. Donini was involved in drug discovery and development at Kinetek Pharmaceuticals, managing a key program with an external partner, as well as initiating and managing a team providing informatics analysis and support to the company at large. Dr. Donini received her PhD in Chemistry from Queen's University in Kingston, Ontario and completed post-doctoral studies at the University of California, San Francisco.
Gayle Mills, Senior Vice President, Business Development
Amgen British Columbia Inc.
7990 Enterprise Street
Burnaby, BC V5A 1V7
Tel. 604 676-8300
Fax. 604 676-8349
investor.relations4id4qg@amgen.com
www.abgenix.com
Jimmy Chang, President
JR Laboratories Inc.
12 - 3871 North Fraser Way
Burnaby, BC V5J 5G6
Tel. 604 432-9311
Fax. 604 432-7768
jchangf4c@jrlabs.ca
infof4c@jrlabs.ca
www.jrlabs.ca
Michael J. Abrams, Ph.D., President & Chief Executive Officer
Inimex Pharmaceuticals Inc.
8540 Baxter Place
Burnaby BC V5A 4T8
Tel. 604 225-2251
Fax. 604 225-2257
infotgzqk@inimexpharma.com
www.inimexpharma.com
Dr. Abrams is the founding CEO of AnorMED, Inc and led that company as President and CEO for ten years. AnorMED discovered and developed Mozobil, a drug for improving stem cell mobilization for patients undergoing stem cell transplantation. Mozobil was approved by FDA in 2008 and AnorMED was acquired by Genzyme Corp. in 2006 for $580M. Prior to AnorMED, Abrams was Manager Biomedical Research for Johnson Matthey, plc where he led the spin-off of the biomedical research group to form AnorMED.
Abrams has a Ph.D. in Chemistry from the Massachusetts Institute of Technology and a BA in Chemistry from Bowdoin College. In 2009 he was a co-recipient of the Georg Charles de Hevesy Nuclear Pioneer Award from the Society of Nuclear Medicine for his work in the invention of the radiopharmaceutical, Cardiolite.
Harlan Lahti, Founder and Technical Consultant
SISU Enterprises Co. Inc.
104A - 3430 Brighton Avenue
Burnaby, BC V5A 3H4
Tel. 604 420-6610
Fax. 604 420-6640
www.sisu.com/sisu
Lahti, 66, is a holistic health pioneer in Canada, having founded Finlandia Pharmacy, a natural health product purveyor in 1975. Lahti travels extensively around the world and has taught students in many countries.
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageDr. Peter Lutwyche, Vice President, Pharmaceutical Development
Tekmira Pharmaceuticals Corporation
200 - 8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Tel. 604 419-3200
Fax. 604 419-3201
infodjt1gfs@inexpharm.com
www.tekmirapharm.com
Dr. Lutwyche joined Tekmira's subsidiary company, Protiva Biotherapeutics Inc., in February 2008, and has responsibility for manufacturing, process development and quality control for all Tekmira product candidates as well as supporting Tekmira's collaborative partners as they advance products based on Tekmira's technology.
Tekmira expects three siRNA product candidates using the company's SNALP delivery technology will be in clinical development in 2009.
Dr. Lutwyche joined Tekmira from QLT Inc., where he was employed for ten years, most recently as Director, Pharmaceutical Development. During his tenure at QLT, Dr. Lutwyche contributed to the development and commercialization of Visudyne as well as leading manufacturing and chemistry efforts for numerous preclinical and clinical stage products.
Prior to QLT, he was a research scientist at Inex Pharmaceuticals Corporation working with lipid-based formulations of nucleic acids and antibiotics. Dr. Lutwyche holds a Ph.D. in Chemistry from the University of British Columbia.
Dr. John Webster, President, Chief Executive Officer and Founder
Welichem Biotech Inc.
316 - 4475 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 432-1703
Fax. 604 432-1704
jwebster3m8x98@welichem.com
info3m8x98@welichem.com
www.welichem.com
Dr. E. Kendall Pye, PhD Biochem., Chief Scientific Officer, Director and founder
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
infopgsp@lignol.ca
www.lignol.ca
Dr. Pye was for 16 years President and CEO, Repap Technologies Inc. and Vice-President, Science and Technology, Repap Enterprises Inc. (Montreal), where he oversaw the Alcell process from which the Lignol process has been developed. Previously, he was a tenured Associate Professor of Biochemistry and Biophysics at the University of Pennsylvania.
He has over 35 years of experience in biotechnology research and consulting in both commercial and academic environments, and is currently engaged in the development of related commercial plants throughout the world. Dr. Pye is a founder and director of Lignol.
Dr. William Armiger, Vice President, Lignin Application Development
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
WArmiger0f76bf5j@lignol.ca
info0f76bf5j@lignol.ca
www.lignol.ca
Dr. Armiger has more than 25 years of experience in the specialty-chemicals, pharmaceutical, biotechnology and environmental-technology industries and is the former CEO and cofounder of BioChemInsights Inc.
He also has extensive experience developing, licensing and commercializing products and process technology for use in industrial biofuels and wastewater treatment. Prior to joining Lignol, Dr. Armiger was engaged as Vice President of Venture Catalysts and also previously held senior consulting positions with The Catalyst Group and Arthur D. Little (“ADL").
Geoff Davis, Ph.D., Chief Scientific Officer
Amgen British Columbia Inc.
7990 Enterprise Street
Burnaby, BC V5A 1V7
Tel. 604 676-8300
Fax. 604 676-8349
www.abgenix.com
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageIan Mortimer, Senior Vice President, Finance and Chief Financial Officer
Tekmira Pharmaceuticals Corporation
200 - 8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Tel. 604 419-3200
Fax. 604 419-3201
info3aswyq@inexpharm.com
www.tekmirapharm.com
Dr. Simon Pimstone, MD, PhD, FRCPC, President, Chief Executive Officer and Co-Founder
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby, BC V5G 4W8
Tel. 604 484-3300
Fax. 604 484-3445
SPimstone6pgt49@xenon-pharma.com
info6pgt49@xenon-pharma.com
www.xenon-pharma.com
Xenon was launched in 1998 by Dr. Pimstone, a South African-born internal medicine specialist who trained with the department of medical genetics at the University of B.C, and chief scientific officer Michael Hayden, a professor of genetics at UBC. They describe Xenon as a clinical genetics-based drug discovery company.
"We believe Xenon has identified more disease-relevant genes, 17 to date, than any other company in the world, and we have advanced a number of those discoveries into drug programs," Pimstone said.
Simon Pimstone is a founder, Director, and President & Chief Executive Officer at Xenon Pharmaceuticals Inc. Dr. Pimstone received his MD from the University of Cape Town.
He is an internal medicine specialist (FRCPC) with an interest in cardiovascular disease. Prior to his specialization, he trained as a clinical research fellow with the Department of Medical Genetics at the University of British Columbia and obtained his PhD through the University of Amsterdam in cardiovascular genetics.
Dr. Pimstone has served as a consultant physician at the St. Paul's Hospital Lipid Clinic in Vancouver, as a Director of the Providence Healthcare Research Trust, a Director of the AllerGEN National Centre of Excellence, an Advisory Member of the SFU Biotech MBA program, and he is a Director of BIOTECanada. Dr. Pimstone is a member of the Young Presidents' Organization.
In 2005, he received the Business in Vancouver Top 40 under 40 Award and the Globe & Mail's Canadian Top 40 Under 40 Award in 2004. Dr. Pimstone is the author of numerous peer-reviewed publications and is also a regular guest speaker at international scientific meetings and healthcare conferences.
Raymond Ma, Vice President of Process Development
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
RMajq47v2v@lignol.ca
infojq47v2v@lignol.ca
www.lignol.ca
Raymond Ma is a well rounded executive with extensive experience in operation, process design, project execution and technology management. He has successfully managed a variety of technology development projects throughout his professional career.
Don Enns, President, Chief Executive Officer and Board Member
CANTEST Ltd. - Burnaby (div. of Maxxam Analytics International Corporation)
4606 Canada Way - Burnaby Life Sciences Centre
Burnaby, BC V5G 1K5
Tel. 604 639-2609 - direct
Tel 604 734-7276
Fax: 604 731-2386
denns8a@cantest.com
cantest8a@cantest.com
www.cantest.com
Don has well over 20 years of laboratory management experience. He obtained his BSc from Trinity Western University and an MBA designation from the University of British Columbia.
He currently sits on the Boards of several local companies in the Life Sciences field and has been President of organizations including the Canadian Association for Environmental Analytical Laboratories (CAEAL) and the BC Water & Waste Association (BCWWA.)
Don has been instrumental in CANTEST's expansion into the European and Southeast Asian markets. His experience overseas includes laboratory consulting such as on new laboratory construction, business development and mergers & acquisitions.
Charles J. Cohen, Vice President, Discovery Research
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby, BC V5G 4W8
Tel. 604 484-3300
Fax. 604 484-3445
CCohen96vjpvck@xenon-pharma.com
info96vjpvck@xenon-pharma.com
www.xenon-pharma.com
February 6, 2008 - Xenon Pharmaceuticals, a drug discovery and development company, announced it has appointed Charles J. Cohen as Vice President, Discovery Research.
"We are delighted to welcome Charlie to the Xenon team" commented Simon Pimstone, Xenon's President and CEO. "Charlie brings a unique combination of drug discovery experience and leadership including in areas that are highly relevant to Xenon such as pain.
With a drug candidate for pain currently in clinical trials, and a backup compound expected to follow, we are certain that Charlie's background will be of great benefit to Xenon. In addition to his experience in the pain area, Charlie brings broad and diverse expertise which will be applicable to our multiple discovery and pre-clinical programs."
Dr. Cohen has spent the past approximately 25 years in the pharmaceutical/biotechnology industry with positions at Bayer Pharmaceuticals, Merck & Co and Vertex Pharmaceuticals. He held senior scientific positions and has published widely in the area of pain and more broadly in cellular neuroscience and neurology. Dr. Cohen received his PhD in Biophysics and Theoretical Biology from the University of Chicago.
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageRajender Kamboj, Ph.D., Executive Vice President, Drug Discovery
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby, BC V5G 4W8
Tel. 604 484-3300
Fax. 604 484-3445
RKamboj7sds38i@xenon-pharma.com
info7sds38i@xenon-pharma.com
www.xenon-pharma.com
Rajender Kamboj, Executive Vice President, Drug Discovery joined Xenon in April 2002. Dr. Kamboj was previously the Vice President and Chief Scientific Officer of Allelix Biopharmaceuticals Inc. (part of NPS Pharmaceuticals, Inc) where he had primary responsibility for managing their drug discovery programs.
In his 12 years with Allelix/NPS, Dr. Kamboj managed research teams covering all aspects of drug discovery and development, from initial research to clinical trials.
Under his leadership at Allelix/NPS, Dr. Kamboj also established, implemented and managed significant corporate partnerships with Eli Lilly, Hoechst Marion Roussel (now Aventis) and Janssen Pharmaceutica (part of Johnson & Johnson).
He led the development of nine drug discovery programs in neurological, metabolic and other therapeutic areas. During his tenure, four drug development programs were independently advanced into clinical studies by Allelix/NPS and three programs partnered with Eli Lilly, Aventis and Johnson & Johnson were advanced into late-stage pre-clinical development. Dr. Kamboj received his PhD from the University of Adelaide in Australia.
Michael Hayden, MD, PhD, FRCPC, Chief Scientific Officer
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby, BC V5G 4W8
Tel. 604 484-3300
Fax. 604 484-3445
MHayden7y8cphsps@xenon-pharma.com
info7y8cphsps@xenon-pharma.com
www.xenon-pharma.com
Michael Hayden has served as our Chief Scientific Officer since March 1999 and has been a member of Xenon's Board of Directors since November 1996.
He is currently a full professor of Medical Genetics at the University of British Columbia, as well as Director of the Center for Molecular Medicine and Therapeutics (CMMT) in Vancouver; the CMMT is a gene research center under UBC's Faculty of Medicine.
Author of over 400 peer-reviewed publications and invited submissions, Dr. Hayden focuses his research primarily on genetic diseases, including genetics of lipoprotein disorders, Huntington's disease and predictive medicine. In association with his colleagues, Dr. Hayden developed the proposal which led to the award of the Canadian Centers of Excellence on the genetic basis of disease.
This effort has been furthered by his involvement in the Canadian Genetic Diseases Network; Dr. Hayden has served as the Network's Scientific Director since its inception in 1990.
Charles LeBlanc, Manager, Environmental Division
CANTEST Ltd. - Burnaby (div. of Maxxam Analytics International Corporation)
4606 Canada Way
Burnaby, BC V5G 1K5
Tel. 604 734-7276
Fax. 604 731-2386
cleblancz6@cantest.com
cantestz6@cantest.com
www.cantest.com
Martin (Marty) McConnell, C.A., Chief Financial Officer
Inimex Pharmaceuticals Inc.
8540 Baxter Place
Burnaby BC V5A 4T8
Tel. 604 225-2251
Fax. 604 225-2257
infow542ce@inimexpharma.com
www.inimexpharma.com
For the past five years Marty has worked with emerging high tech and Biotech companies as part-time CFO focused on strategic financial issues. For the prior 18 years he was CFO for two midsize public (TSX, Nasdaq) Canadian high tech companies, from 1993 to 2002 with Spectrum Signal Processing Inc. and from 1985 to 1993 at Epic Data International Inc. Mr. McConnell holds a B. Comm. from the University of British Columbia and is a Chartered Accountant.
Liren Tang, Ph.D., Head of Life Science
Welichem Biotech Inc.
316 - 4475 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 432-1703
Fax. 604 432-1704
lirentanggja1d@welichem.com
infogja1d@welichem.com
www.welichem.com
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageOwen Granger, Chief Financial Officer and Director
Lifebank Cryogenics Corporation
200 - 4475 Wayburne Drive
Burnaby, BC V5G 4X4
Tel. 604 738-2722
Fax. 604 738-2726
lifeydz4o0@lifebank.com
www.lifebank.com
Mr. Granger received a B.A. (honors) from the faculty of Business Administration, Simon Fraser University, in 1981 and has been a Certified Management Accountant since 1986. From 1983 to date he has been employed in a variety of senior accounting and financial management positions for public enterprises. He has been a director and senior financial officer of companies listed on the TSE, TSX, NASDAQ and over-the-counter markets.
In addition, since 1989, he has been a director and the part-time secretary treasurer of WestBond Enterprises Corporation, a public company engaged in the manufacture of disposable paper and polyethylene products for the medical, airline and industrial markets.
Paul Hughes, Vice President, Corporate Development and Communications
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 222-9800 X 110 - direct
Tel. 604 222-9800
Fax. 604 222-9801
phughesffp@lignol.ca
infoffp@lignol.ca
www.lignol.ca
Paul Hughes has extensive international experience and expertise within the alternative/renewable energy sector gained within North America, Europe and Asia.
Mr. Hughes has co-founded energy companies in Europe and North America, has led an energy company from start-up through to IPO and has successfully raised private equity within multiple energy technology companies.
Mr. Hughes has also held senior business development and corporate finance roles in the UK and US utilities. Mr. Hughes holds a BSc (Hons) in Business from Aston University, UK, an Executive MBA from Ashridge, UK and is a Chartered Accountant.
Brent Hale, Director, Human Resources
CANTEST Ltd. - Burnaby (div. of Maxxam Analytics International Corporation)
4606 Canada Way
Burnaby, BC V5G 1K5
Tel. 604 639-8420 - direct
Tel. 604 734-7276
Fax. 604 731-2386
bhalefr3m3p@cantest.com
cantestfr3m3p@cantest.com
www.cantest.com
January 30, 2007 - CANTEST Ltd. is pleased to announce the addition of Brent Hale as Director, Human Resources at CANTEST.
In addition to his in-depth knowledge of employment and labour law matters, Mr. Hale has experience in all areas of HR including compensation, recruitment, communications, organizational and leadership development and change management.
Dr. Alex Berlin, Vice President of Research
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
ABerlin9419@lignol.ca
info9419@lignol.ca
www.lignol.ca
Dr. Berlin developed postdoctoral R&D work in biorefinery of lignocellulosics at the Forest Products Biotechnology Group, Faculty of Forestry, University of British Columbia (Vancouver, BC, Canada). He has more than 15 years of R&D experience in this area including expertise in substrate pretreatment technologies, enzymatic hydrolysis of lignocellulosics, carbohydrate fermentation into cellulosic ethanol and other products, and development of lignin-based high-added value co-products.
He has authored or co-authored more than 50 scientific publications and invention patents. Dr. Berlin has extensive international industrial experience in business development for the Eastern European, South and North American biotech markets (bio-ethanol, food, and enzyme technologies).
Brian Edgar, President
SISU Enterprises Co. Inc.
104A - 3430 Brighton Avenue
Burnaby, BC V5A 3H4
Tel. 604 420-6610
Fax. 604 420-6640
www.sisu.com/sisu
Edgar is also President of Dome Ventures Corporation, which owns SISUS Enterprises. He is also a director of the Pender Growth Fund Inc.
Brian Edgar has been active in public markets for two decades. A graduate of University of British Columbia law school, Mr. Edgar spent his early career as an associate with the firm of Rand, McLaughlin, Gorham & Tolmie, specializing in securities and corporation law.
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageMichael Rushton, P.Eng., Chief Operating Officer
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
MRushtonjesi1@lignol.ca
infojesi1@lignol.ca
www.lignol.ca
Rushton is a chemical engineer and business executive with more than 25 years of experience in the development and commercialization of technology. Mr. Rushton started his career in the oil industry and has subsequently been involved in the supply of technology to the pulp and paper, metal smelting and chemical process industries.
Most recently, Mr. Rushton has been involved with emerging technology in the alternative energy sector where he was President and CEO of Membrane Reactor Technologies Ltd.
Ray Cheung, Laboratory Director
JR Laboratories Inc.
12 - 3871 North Fraser Way
Burnaby, BC V5J 5G6
Tel. 604 432-9311
Fax. 604 432-7768
rcheung09@jrlabs.ca
info09@jrlabs.ca
www.jrlabs.ca
Ray graduated from UBC with a BSc (Food Science) in 1975. He has worked as a microbiology lab technician at Provincial Health Laboratory before joining BC Provincial Dairy and Food Laboratory, where he supervised staff testing raw and finished dairy products.
In 1988, the provincial government privatized the Dairy Testing Laboratory. Ray and associates purchased the laboratory and in 1989, JR Laboratories Inc. was formed. Ray is a major shareholder and Laboratory Director, while his partner, Jimmy Chang, is the President. JR Laboratories Inc. continues to be the only BC government designated and certified lab for dairy and food analysis.
Tom Redelmeier, President and Chief Executive Officer
Northern Lipids Inc.
8855 Northbrook Court
Burnaby, BC V5J 5J1
Tel. 604 222-2548
Fax. 604 222-2563
infoeznae8@northernlipids.com
www.northernlipids.com
